Louis-Paul Marin Presents AppMed at LSI Europe '23

Transcription

Louis-Paul Marin  0:05  
Hello, thank you all for being here and LSI for having AppMed as part of this great meeting. From the get go, I always listened to my lawyers. I'm sorry, I can't live with them can't live without them. Sorry for my bad French Canadian accent, you'll have to bear with it. I'm here today to introduce you to AppMed. AppMed is a startup company based in Montreal, Canada. We developed a mobile application, it's a medical mobile application targeting the needs of both caregivers and patients. It's an app which is power, patients centered. We wanted to empower the patient give them control over who they connect to the app. It simplifies the treatment process. It enhances communications between caregivers, but between caregivers and their patients. This without fundamentally changing the whole clinical process. It's meant to be used to optimize therapeutic drug monitoring, and also to personalize that drug dosing. Our first application indication is for patients whether adults, adolescents or children suffering from Attention Deficit Hyperactivity Disorder, ADHD. Why ADHD? While it's a global problem, the prevalence is roughly between two and 7%. Also, I'm a parent of two kids who are now medicated with ADHD drugs. And I noticed that you know, currently, even though the medications have been prescribed for over 50 years, it's done on a sort of best guess estimates, right? Clinical judgment. You come in the office, when once you get diagnosed, for instance, and they will be prescribed with small dose, you'll go home, the kids will try out for a couple of weeks, then you'll go back, the physician will make an assessment in his office based on a few questions and maybe raised the dose up and until it is believed that the dose is adequate. There is a big lack of feedback on the parents side. Because you don't know whether how the kids medicated whether it works or not. It's really difficult to make this assessment you just question your kid. But again, they're 789 years old, on the phishing site, they don't have much time in their office. So there's a big issue there that needed to be resolved. So we developed RP, our first product, it was developed around the computerized tool, which computes and displays pharmacokinetic profiles in real time. It displays these pharmacokinetic of displays pharmacokinetic profiles of different drug regimens, it allows the physician to really see what the ideal dosage is, for a certain formulation. It also allows the physician to compare certain different formulations and also different combinations, because sometimes you medicate the kid in the morning, and the medical coverage needs to be extended up and until they're completing their homeworks at night. Also, this tool is useful because it can be used by the caregivers to show the patient how the medication acts, what are the what is the medical coverage, it really helps the patient to understand why they're taking the medication and what it's going to do and where when it's going to affect the when it's gonna be efficient. We also complemented this with questionnaires, which were digitally embedded within RP. The problem is that these questionnaires do exist right now. But they're paper based. So it's very difficult for the parents to complete them. But even more complicated when you give them to the physicians at the office, because they only have a short window, you know that they have maybe 1015 minutes with you in the office. And these questionnaires. You know, they're it's questions that are scored. And the scores at the end are complicated to calculate. It takes time. So they're never used right now. by inputting you know, all these digital questionnaires within RP. What it does is actually calculate the scores automatically and inputs, the data within the tabulations or the graph within RP. so the physician can see exactly what's happening. What are the side effects that were reported and how the patient's behaved. back in time, more a lot more importantly, what we did is we added some questionnaires, which are intended to be used by the teachers at school, or by the baseball coaches or everyone that is actually involved in the daily context, which means that you have on one end the pharmacokinetic profiles, sort of the ideal dosage that you can compare with clinical data that are sort of real world evidence. And by combining both, you can have a good assessment of how the drug is how efficient is the drug. We also complemented our app with monitoring tools that are meant to be used by the physician to freely visualize assessment results, as well as those prescriptions. We developed those tools, with the help of pharmacists and physicians. So they really see at first glance exactly what's happening, what is being done, and they can compare the results, or the efficacy of the drug with the prescriptions. How will we monetize this, I think, probably of interest of a few people here. Well, we've launched the product in Canada, because it's already approved. We the first launch is sort of a pilot commercial commercialization project. With a pharmacy group in Montreal. It's a subscription model. With health professionals, they pay us on a sort of per patient enrolled a basis. We look forward now to launch with an directly target the patients who will in turn enroll their physicians or their pharmacists. We also are discussing with clinical sorry, with pharmaceutical companies. We're looking forward to using Appy to monitor patient while they're conducting their own trials for the efficacy purposes or to actually look at side effects. And once we have a lot of data, we're looking also to implement some AI driven functionalities. Also, we are currently finalizing the validation of diagnostic tests, where we are determined which is used to determine the drug levels in saliva, which correlates with the plasma levels and we will sell this and the results will be inputted within Appy so, we hope to have Appy promoted indirectly by this test, but also the data will be used to even to even be more precise whenever we look at the pharmacokinetic profiles will be able to place in the matrix from a patient directly in be even more precise with the way the curves are going to be displayed. Also, we look forward, we hope that the physician will be able to use this whenever unexpected side effects are detected to see exactly why there's some side effects or are happening or also detect when the patient does not react to the drug. Because you'll see sometimes the metabolism may have an effect and that might be a way to detect the patients which are metabolizing too fastly or too slowly. So as I said earlier, we're already launched in Canada with the pharmacy group. And we have a partner nufarm Who's going to be the partner for the development validation conversation of the diagnostic tests. We also wish to diversify. We are currently working on a pain management version of the app. We've already signed the deal with the Children's Hospital in Montreal, we have a partnership with two pain clinics, same type of application, except in pain management. Right now we add we conducted a small study at the Children's Hospital to monitor patients for pain management after surgery at home. Our app is actually validated according to industry standards. It didn't approved by Health Canada, as I said as a class to medical device. We have two patents. Granted one in Canada in one of the US, patents are currently covering the pathology and how we come up with the pharmacokinetics. And we have the second one which has been filed very recently. It's a patent application covering the link between the drug test and the drug, the diagnostic test results and the pharmacokinetic curves. We have a team of experts. I'm sorry the time does not work. How much How long do I have still? I mean, I don't So how much time I have left? Okay, sorry. Thank you. So anyway, we have a great team. We're three people. I am a trained engineer, lawyer on my team, we have a programmer and tax specialist, and we welcome you to join our mission.